Citation

Bacci G, Balladelli A, Forni C, Ferrari S, Longhi A, Benassi MS, Briccoli A, Serra M, Picci P. Ann. Oncol. 2007; 18(12): 2037-2040.

Copyright

(Copyright © 2007, Oxford University Press)

DOI

10.1093/annonc/mdm382

PMID

17962210

Abstract

BACKGROUND: In 326 patients with Ewing's sarcoma family tumor (ESFT) and 628 extremity osteosarcoma (OS) treated with adjuvant and neo-adjuvant chemotherapy and event-free survivors 5 years from the beginning of treatment we evaluated outcome in the following years. Post 5-year follow-up for these patients was 9.7 years (5.5-29 years).
PATIENTS AND METHODS: Adverse events observed after 5-year follow-up were 73 (7.6%): 38 late relapses, nine leukemia, 14 second solid tumor, seven radioinduced sarcoma, three severe adriamycin-related cardiomyopathy, one suicide and one death by car crash.
RESULTS: Of the patients who developed late events, 16 (22.5%) are alive and event free after 8 years from the last treatment (2-22 years).
CONCLUSION: We conclude that the high rate of late adverse events after 5 years in patients with OS and ESFT is noteworthy and indicates that these patients should be followed for >5 years.

Language: en

Keywords

Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Extremities; Humans; Osteosarcoma; Sarcoma, Ewing; Treatment Outcome